The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers.
Anna BalatoAlexander ZinkGraziella BabinoDario BuononatoCharlotte KianiKilian EyerichStefanie ZiehfreundEmanuele ScalaPublished in: Life (Basel, Switzerland) (2022)
Psoriasis (PSO) and Atopic dermatitis (AD) are common inflammatory skin diseases that affect people of all ages globally. They negatively impact the quality of life (QoL) of patients in health-related aspects such as physical, psychological and mental functioning. Here, we conducted a review of studies relating to candidate biomarkers and indicators associated with QoL impairment in PSO and AD. Data research was performed using PUBMED and SCOPUS databases from inception to September 2022. Most of the included studies reported genomic or proteomic biomarkers associated with disease activity and QoL outcomes. Sociodemographic, clinical and therapeutic factors have also been implicated in deterioration of life quality in these patients. The inclusion of clinical characteristics, QoL impairment and co-diagnosis should be considered in drug development programs, since processing biomarkers based on an increased number of features in addition to drug class and disease will intensify the value of the biomarker itself, thereby maximizing the future clinical utility as a stratification tool.
Keyphrases
- atopic dermatitis
- end stage renal disease
- disease activity
- chronic kidney disease
- newly diagnosed
- rheumatoid arthritis
- ejection fraction
- systemic lupus erythematosus
- prognostic factors
- systematic review
- peritoneal dialysis
- public health
- gene expression
- patient reported outcomes
- big data
- oxidative stress
- ankylosing spondylitis
- adipose tissue
- copy number
- juvenile idiopathic arthritis
- electronic health record
- wound healing
- soft tissue